ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,130.11
-0.09%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) Noticias

NRIX Nurix Therapeutics Inc

15.18
-1.55 (-9.26%)
14 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Nurix Therapeutics Inc NRIX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-1.55 -9.26% 15.18 23:00:07
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
16.51 14.862 16.59 15.18 16.73
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202417:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202418:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202415:06EDGAR2Form S-3ASR - Automatic shelf registration statement of..
10/6/202406:00GLOBENurix Therapeutics to Host a Webcast and Conference Call to..
05/6/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202417:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202415:58EDGAR2Form 144 - Report of proposed sale of securities
29/5/202406:00GLOBENurix Therapeutics to Participate in the Jefferies Global..
28/5/202406:00GLOBENurix Therapeutics Appoints Paula G. O’Connor, M.D., as..
21/5/202406:06EDGAR2Form 8-K - Current report
20/5/202418:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202418:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202415:00GLOBENurix Therapeutics Announces Board Chair Transition
14/5/202409:00GLOBENurix Therapeutics Announces Upcoming Oral Presentation of..
07/5/202406:00GLOBENurix Therapeutics to Participate in RBC Capital Markets..
16/4/202417:21GLOBENurix Therapeutics Announces Closing of Public Offering and..
11/4/202422:38GLOBENurix Therapeutics Announces Pricing of Upsized $175.0..
11/4/202415:00GLOBENurix Therapeutics Announces Proposed Public Offering
10/4/202406:00GLOBENurix Therapeutics Reports First Quarter Fiscal 2024..
09/4/202412:15GLOBENurix Therapeutics Reports First Clinical Evidence of CNS..
09/4/202406:00GLOBENurix Therapeutics Announces Extension of Strategic..
03/4/202406:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
02/4/202406:00GLOBENurix Therapeutics Announces Extension of Strategic..
25/3/202406:00GLOBENurix Therapeutics is Part of a Team of International..
20/3/202408:40GLOBENurix Presents the Discovery and Chemical Structure of..
11/3/202406:02EDGAR2Form 8-K - Current report
11/3/202406:00GLOBENurix Therapeutics Announces U.S. FDA Lifts Partial Clinical..
06/3/202415:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
05/3/202415:30GLOBENurix Therapeutics Announces Presentations at the American..
16/2/202418:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:22EDGAR2Form 144 - Report of proposed sale of securities
15/2/202415:51EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/2/202415:01EDGAR2Form 8-K - Current report
15/2/202415:00GLOBENurix Therapeutics Reports Fourth Quarter and Fiscal Year..
15/2/202406:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202406:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202406:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202407:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202415:01GLOBENurix Therapeutics Announces Publication in the Journal..
30/1/202417:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202417:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202417:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202415:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/1/202415:48DJNNurix Therapeutics Gets FDA Fast-Track Designation for..
16/1/202415:01GLOBENurix Therapeutics Receives U.S. FDA Fast Track Designation..
08/1/202406:03EDGAR2Form 8-K - Current report
08/1/202406:00GLOBENurix Therapeutics Outlines 2024 Strategic Priorities with..
02/1/202415:01GLOBENurix Therapeutics to Present at 42nd Annual J.P. Morgan..
21/12/202316:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
NRIX
Nurix Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados